Hideki Fujii

Asahimachi, 5458585, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 419 publications

Delisting From Clinical Improvement in Liver Cirrhosis: A Machine Learning Decision Tree Analysis.

Delisting From Clinical Improvement in Liver Cirrhosis: A Machine Learning Decision Tree Analysis.

Journal: Transplantation

Published: June 16, 2026

Traction-assisted Endoscopic Retrograde Cholangiopancreatography Using an S-O Clip for Difficult Biliary Cannulation in Billroth II Reconstruction With Tumor-associated Distortion.

Traction-assisted Endoscopic Retrograde Cholangiopancreatography Using an S-O Clip for Difficult Biliary Cannulation in Billroth II Reconstruction With Tumor-associated Distortion.

Journal: DEN open

Published: June 08, 2026

Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.

Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.

Journal: Anticancer research

Published: May 14, 2026

Generalizability of the MetALD-ALD Prediction Index in Asian Populations.

Generalizability of the MetALD-ALD Prediction Index in Asian Populations.

Journal: Gastroenterology

Published: April 24, 2026

ENVELOPE: enfortumab vedotin in patients with advanced small bowel adenocarcinoma refractory or intolerant to platinum-based therapy-phase II investigator-initiated trial (NCCH2412/MK015).

ENVELOPE: enfortumab vedotin in patients with advanced small bowel adenocarcinoma refractory or intolerant to platinum-based therapy-phase II investigator-initiated trial (NCCH2412/MK015).

Journal: ESMO gastrointestinal oncology

Published: April 20, 2026

Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 2026.

Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 2026.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: April 03, 2026

Reply to "Reappraisal of the MASLD predictive factors: insights beyond the surface".

Reply to "Reappraisal of the MASLD predictive factors: insights beyond the surface".

Journal: Journal of gastroenterology

Published: March 25, 2026

From dietary patterns to metabolic phenotypes in MASLD: promise and caution.

From dietary patterns to metabolic phenotypes in MASLD: promise and caution.

Journal: Hepatology international

Published: February 25, 2026

Reply to "Rethinking screening strategies for non-obese individuals at risk for MASLD: a clinical perspective on metabolic vulnerability".

Reply to "Rethinking screening strategies for non-obese individuals at risk for MASLD: a clinical perspective on metabolic vulnerability".

Journal: Journal of gastroenterology

Published: February 23, 2026

Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026.

Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026.

Journal: Journal of gastroenterology

Published: February 21, 2026

A case of endoscopic therapy using electrohydraulic lithotripsy under peroral pancreatoscopy via the minor papilla.

A case of endoscopic therapy using electrohydraulic lithotripsy under peroral pancreatoscopy via the minor papilla.

Journal: Endoscopy

Published: February 17, 2026

Metabolic Burden and Hyperuricemia Are Associated With CKD-Related Outcomes in Individuals With and Without Steatotic Liver Disease.

Metabolic Burden and Hyperuricemia Are Associated With CKD-Related Outcomes in Individuals With and Without Steatotic Liver Disease.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: January 30, 2026

Showing 1-12 of 419

Last Updated: 09/26/2026